Status:
COMPLETED
Effects of Combined Metformin and Cabergoline in Comparison With Metformin Only Therapy on Ovarian and Hormonal Activities in Iraqi Patients With PCOS
Lead Sponsor:
Al-Rasheed University College
Conditions:
Polycystic Ovary Syndrome
Eligibility:
FEMALE
18-40 years
Phase:
PHASE2
Brief Summary
The goal of this interventional Randomized clinical is to compare the effect of Metformin alone, Cabergoline alone and Metformin and Cabergoline in combination in a sample of Iraqi female patients wit...
Eligibility Criteria
Inclusion
- Age 18 - 40 years
- Diagnosed with Polycystic Ovarian Syndrome based on Rotterdam criteria
- Body Mass Index (BMI) \< 40 Kg/m²
Exclusion
- Age less than 18 years or more than 40 years
- Co-morbid conditions including (diabetes mellitus, essential hypertension, and thyroid disease)
- Patients planning for conception.
- Body Mass Index \> 40 Kg/m²
Key Trial Info
Start Date :
September 21 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 31 2023
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT05981742
Start Date
September 21 2022
End Date
March 31 2023
Last Update
August 8 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Maternity and Pediatric Teaching Hospital
Al Qādisīyah, Al-Qādisiyyah Governorate, Iraq, 58001